Artisan Partners Limited Partnership increased its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 4.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,177,981 shares of the medical instruments supplier's stock after purchasing an additional 95,549 shares during the quarter. Artisan Partners Limited Partnership owned 1.10% of DENTSPLY SIRONA worth $41,338,000 as of its most recent filing with the SEC.
Other hedge funds have also recently bought and sold shares of the company. UMB Bank n.a. lifted its stake in shares of DENTSPLY SIRONA by 60.8% during the fourth quarter. UMB Bank n.a. now owns 1,492 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 564 shares in the last quarter. MML Investors Services LLC lifted its position in DENTSPLY SIRONA by 2.1% during the 3rd quarter. MML Investors Services LLC now owns 29,682 shares of the medical instruments supplier's stock worth $803,000 after acquiring an additional 620 shares in the last quarter. Blue Trust Inc. boosted its holdings in DENTSPLY SIRONA by 10.9% in the 4th quarter. Blue Trust Inc. now owns 7,199 shares of the medical instruments supplier's stock worth $137,000 after acquiring an additional 707 shares during the period. MassMutual Private Wealth & Trust FSB raised its stake in shares of DENTSPLY SIRONA by 648.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,422 shares of the medical instruments supplier's stock valued at $27,000 after purchasing an additional 1,232 shares during the period. Finally, Riverview Trust Co purchased a new stake in shares of DENTSPLY SIRONA during the fourth quarter valued at approximately $26,000. Hedge funds and other institutional investors own 95.70% of the company's stock.
Insider Buying and Selling at DENTSPLY SIRONA
In other news, Director Gregory T. Lucier purchased 15,142 shares of the company's stock in a transaction on Monday, March 3rd. The shares were bought at an average price of $16.51 per share, for a total transaction of $249,994.42. Following the completion of the purchase, the director now owns 81,971 shares of the company's stock, valued at $1,353,341.21. This trade represents a 22.66 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.52% of the stock is currently owned by company insiders.
DENTSPLY SIRONA Stock Performance
Shares of NASDAQ:XRAY traded up $0.08 during trading on Wednesday, hitting $14.73. 398,028 shares of the company traded hands, compared to its average volume of 2,769,799. The stock has a market capitalization of $2.93 billion, a price-to-earnings ratio of -7.11, a PEG ratio of 1.80 and a beta of 0.98. DENTSPLY SIRONA Inc. has a one year low of $14.50 and a one year high of $33.02. The company has a quick ratio of 0.84, a current ratio of 1.25 and a debt-to-equity ratio of 0.72. The business's fifty day moving average is $17.55 and its 200-day moving average is $20.05.
DENTSPLY SIRONA Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, April 11th. Shareholders of record on Friday, March 28th will be given a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 4.34%. The ex-dividend date is Friday, March 28th. DENTSPLY SIRONA's dividend payout ratio is presently -14.07%.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on XRAY shares. Morgan Stanley lowered their price target on shares of DENTSPLY SIRONA from $30.00 to $23.00 and set an "overweight" rating for the company in a report on Tuesday, December 17th. Jefferies Financial Group downgraded DENTSPLY SIRONA from a "buy" rating to a "hold" rating and lowered their target price for the company from $30.00 to $20.00 in a research note on Thursday, January 23rd. Evercore ISI reiterated an "in-line" rating and issued a $20.00 price target on shares of DENTSPLY SIRONA in a research note on Tuesday, January 7th. StockNews.com lowered DENTSPLY SIRONA from a "buy" rating to a "hold" rating in a research note on Friday, February 28th. Finally, Barrington Research reduced their target price on DENTSPLY SIRONA from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Friday, February 28th. Twelve equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $23.33.
Check Out Our Latest Stock Report on XRAY
DENTSPLY SIRONA Profile
(
Free Report)
DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.
See Also

Before you consider DENTSPLY SIRONA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DENTSPLY SIRONA wasn't on the list.
While DENTSPLY SIRONA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.